Previous close | 2.6500 |
Open | 2.4500 |
Bid | 1.5000 |
Ask | 2.6500 |
Strike | 125.00 |
Expiry date | 2023-10-20 |
Day's range | 2.4500 - 2.4500 |
Contract range | N/A |
Volume | |
Open interest | 74 |
Ensign Group (ENSG) remains well-poised for growth on the back of a growing revenue base, continuous pursuit of acquisitions and commendable financial position.
Scynexis (SCYX) enters an exclusive license agreement with GSK to commercialize Brexafemme (ibrexafungerp), an antifungal tablet. GSK will also continue to develop ibrexafungerp for treating invasive candidiasis.
Ozempic is a drug that has been soaring in popularity over the past year. Three companies that can benefit from the excitement around this weight-loss treatments are Novo Nordisk (NYSE: NVO), Eli Lilly (NYSE: LLY), and WW International (NASDAQ: WW). The biggest benefactor of Ozempic's popularity is likely to be the company that makes the treatment itself: Novo Nordisk.